

Epstein-Barr Virus

References to Supplementary Web Tables, Section 2

- Akre O, Lipworth L, Tretli S *et al.* (1999). Epstein-Barr virus and cytomegalovirus in relation to testicular-cancer risk: a nested case-control study. *Int J Cancer*, 82:1–5.[doi:10.1002/\(SICI\)1097-0215\(19990702\)82:1<1::AID-IJC1>3.0.CO;2-L](https://doi.org/10.1002/(SICI)1097-0215(19990702)82:1<1::AID-IJC1>3.0.CO;2-L) PMID:10360811
- Alexander FE, Jarrett RF, Lawrence D *et al.* (2000). Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. *Br J Cancer*, 82:1117–1121. PMID:10737396
- Alexander FE, Lawrence DJ, Freeland J *et al.* (2003). An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. *Int J Cancer*, 107:298–302.[doi:10.1002/ijc.11156](https://doi.org/10.1002/ijc.11156) PMID:12949811
- Berrington de González A, Urban MI, Sitas F *et al.* (2006). Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case control study. *Infect Agent Cancer*, 1:2.[doi:10.1186/1750-9378-1-2](https://doi.org/10.1186/1750-9378-1-2) PMID:17150131
- Carpenter LM, Newton R, Casabonne D *et al.* (2008). Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. *Int J Cancer*, 122:1319–1323.[doi:10.1002/ijc.23254](https://doi.org/10.1002/ijc.23254) PMID:18000823
- Chen MR, Liu MY, Hsu SM *et al.* (2001). Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients. *J Med Virol*, 64:51–57.[doi:10.1002/jmv.1017](https://doi.org/10.1002/jmv.1017) PMID:11285569
- Chien YC, Chen JY, Liu MY *et al.* (2001). Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. *N Engl J Med*, 345:1877–1882.[doi:10.1056/NEJMoa011610](https://doi.org/10.1056/NEJMoa011610) PMID:11756578
- de Sanjosé S, Bosch R, Schouten T *et al.* (2007). Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. *Int J Cancer*, 121:1806–1812.[doi:10.1002/ijc.22857](https://doi.org/10.1002/ijc.22857) PMID:17557295
- Dinand V, Dawar R, Arya LS *et al.* (2007). Hodgkin's lymphoma in Indian children: prevalence and significance of Epstein-Barr virus detection in Hodgkin's and Reed-Sternberg cells. *Eur J Cancer*, 43:161–168.[doi:10.1016/j.ejca.2006.08.036](https://doi.org/10.1016/j.ejca.2006.08.036) PMID:17113770
- Fan H, Nicholls J, Chua D *et al.* (2004). Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. *Int J Cancer*, 112:1036–1041.[doi:10.1002/ijc.20520](https://doi.org/10.1002/ijc.20520) PMID:15386346
- Gallagher A, Armstrong AA, MacKenzie J *et al.* (1999). Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. *Int J Cancer*, 84:442–448.[doi:10.1002/\(SICI\)1097-0215\(19990820\)84:4<442::AID-IJC20>3.0.CO;2-J](https://doi.org/10.1002/(SICI)1097-0215(19990820)84:4<442::AID-IJC20>3.0.CO;2-J) PMID:10404101
- Glaser SL, Keegan TH, Clarke CA *et al.* (2005). Exposure to childhood infections and risk of Epstein-Barr virus-defined Hodgkin's lymphoma in women. *Int J Cancer*, 115:599–605.[doi:10.1002/ijc.20787](https://doi.org/10.1002/ijc.20787) PMID:15700307
- Hardell E, Eriksson M, Lindström G *et al.* (2001a). Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma. *Leuk Lymphoma*, 42:619–629.[doi:10.3109/10428190109099322](https://doi.org/10.3109/10428190109099322) PMID:11697490
- Hardell L, Lindström G, van Bavel B *et al.* (2001b). Adipose tissue concentrations of dioxins and dibenzofurans, titers of antibodies to Epstein-Barr virus early antigen and the risk for non-Hodgkin lymphoma. *Environ Res*, 87:99–107.[doi:10.1006/enrs.2001.4295](https://doi.org/10.1006/enrs.2001.4295) PMID:11683593
- Hjalgrim H, Askling J, Sørensen P *et al.* (2000). Risk of Hodgkin's disease and other cancers after infectious mononucleosis. *J Natl Cancer Inst*, 92:1522–1528.[doi:10.1093/jnci/92.18.1522](https://doi.org/10.1093/jnci/92.18.1522) PMID:10995808
- Hjalgrim H, Smedby KE, Rostgaard K *et al.* (2007). Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. *Cancer Res*, 67:2382–2388.[doi:10.1158/0008-5472.CAN-06-3566](https://doi.org/10.1158/0008-5472.CAN-06-3566) PMID:17332371

- Ji MF, Wang DK, Yu YL *et al.* (2007). Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. *Br J Cancer*, 96:623–630.[doi:10.1038/sj.bjc.6603609](https://doi.org/10.1038/sj.bjc.6603609) [PMID:17285127](https://pubmed.ncbi.nlm.nih.gov/17285127/)
- Koshiol J, Qiao YL, Mark SD *et al.* (2007). Epstein-Barr virus serology and gastric cancer incidence and survival. *Br J Cancer*, 97:1567–1569.[doi:10.1038/sj.bjc.6604063](https://doi.org/10.1038/sj.bjc.6604063) [PMID:17987041](https://pubmed.ncbi.nlm.nih.gov/17987041/)
- Lei KI, Chan LY, Chan WY *et al.* (2000). Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. *Br J Haematol*, 111:239–246.[doi:10.1046/j.1365-2141.2000.02344.x](https://doi.org/10.1046/j.1365-2141.2000.02344.x) [PMID:11091207](https://pubmed.ncbi.nlm.nih.gov/11091207/)
- Leung SF, Tam JS, Chan AT *et al.* (2004). Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. *Clin Chem*, 50:339–345.[doi:10.1373/clinchem.2003.022426](https://doi.org/10.1373/clinchem.2003.022426) [PMID:14684618](https://pubmed.ncbi.nlm.nih.gov/14684618/)
- Lin JC, Wang WY, Chen KY *et al.* (2004). Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. *N Engl J Med*, 350:2461–2470.[doi:10.1056/NEJMoa032260](https://doi.org/10.1056/NEJMoa032260) [PMID:15190138](https://pubmed.ncbi.nlm.nih.gov/15190138/)
- Lin SY, Tsang NM, Kao SC *et al.* (2001). Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. *Head Neck*, 23:194–200.[doi:10.1002/1097-0347\(200103\)23:3<194::AID-HED1018>3.0.CO;2-X](https://doi.org/10.1002/1097-0347(200103)23:3<194::AID-HED1018>3.0.CO;2-X)[doi:10.1002/1097-0347\(200103\)23:3<194::AID-HED1018>3.0.CO;2-X](https://doi.org/10.1002/1097-0347(200103)23:3<194::AID-HED1018>3.0.CO;2-X) [PMID:11428449](https://pubmed.ncbi.nlm.nih.gov/11428449/)
- Lo YM, Chan LY, Lo KW *et al.* (1999). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. *Cancer Res*, 59:1188–1191. [PMID:10096545](https://pubmed.ncbi.nlm.nih.gov/10096545/)
- Lo YM, Chan WY, Ng EK *et al.* (2001). Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. *Clin Cancer Res*, 7:1856–1859. [PMID:11448896](https://pubmed.ncbi.nlm.nih.gov/11448896/)
- Mitarnun W, Suwiwat S, Pradutkanchana J *et al.* (2002). Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis. *Am J Hematol*, 70:31–38.[doi:10.1002/ajh.10094](https://doi.org/10.1002/ajh.10094) [PMID:11994979](https://pubmed.ncbi.nlm.nih.gov/11994979/)
- Musacchio JG, Carvalho MdaG, Morais JC *et al.* (2006). Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease. *Sao Paulo Med J*, 124:154–157.[doi:10.1590/S1516-31802006000300009](https://doi.org/10.1590/S1516-31802006000300009) [PMID:17119693](https://pubmed.ncbi.nlm.nih.gov/17119693/)
- Mutalima N, Molyneux E, Jaffe H *et al.* (2008). Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. *PLoS One*, 3:e2505.[doi:10.1371/journal.pone.0002505](https://doi.org/10.1371/journal.pone.0002505) [PMID:18560562](https://pubmed.ncbi.nlm.nih.gov/18560562/)
- Mutirangura A, Pornthanakasem W, Theamboonlers A *et al.* (1998). Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. *Clin Cancer Res*, 4:665–669. [PMID:9533535](https://pubmed.ncbi.nlm.nih.gov/9533535/)
- Newton R, Carpenter L, Casabonne D *et al.* (2006). A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1. *Br J Cancer*, 94:1504–1509.[doi:10.1038/sj.bjc.6603100](https://doi.org/10.1038/sj.bjc.6603100) [PMID:16705315](https://pubmed.ncbi.nlm.nih.gov/16705315/)
- Richardson AK, Cox B, McCredie MR *et al.* (2004). Cytomegalovirus, Epstein-Barr virus and risk of breast cancer before age 40 years: a case-control study. *Br J Cancer*, 90:2149–2152. [PMID:15150559](https://pubmed.ncbi.nlm.nih.gov/15150559/)
- Sand LP, Jalouli J, Larsson PA, Hirsch JM (2002). Prevalence of Epstein-Barr virus in oral squamous cell carcinoma, oral lichen planus, and normal oral mucosa. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 93:586–592.[doi:10.1067/moe.2002.124462](https://doi.org/10.1067/moe.2002.124462) [PMID:12075209](https://pubmed.ncbi.nlm.nih.gov/12075209/)
- Shinkura R, Yamamoto N, Koriyama C *et al.* (2000). Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan. *J Med Virol*, 60:411–416.[doi:10.1002/\(SICI\)1096-9071\(200004\)60:4<411::AID-JMV8>3.0.CO;2-8](https://doi.org/10.1002/(SICI)1096-9071(200004)60:4<411::AID-JMV8>3.0.CO;2-8) [PMID:10686024](https://pubmed.ncbi.nlm.nih.gov/10686024/)
- Suwiwat S, Pradutkanchana J, Ishida T, Mitarnun W (2007). Quantitative analysis of cell-free Epstein-Barr virus DNA in the plasma of patients with peripheral T-cell and NK-cell lymphomas and peripheral T-cell proliferative diseases. *J Clin Virol*, 40:277–283.[doi:10.1016/j.jcv.2007.08.013](https://doi.org/10.1016/j.jcv.2007.08.013) [PMID:17996493](https://pubmed.ncbi.nlm.nih.gov/17996493/)
- Szkaradkiewicz A, Kruk-Zagajewska A, Wal M *et al.* (2002). Epstein-Barr virus and human papillomavirus infections and oropharyngeal squamous cell carcinomas. *Clin Exp Med*, 2:137–141.[doi:10.1007/s102380200019](https://doi.org/10.1007/s102380200019) [PMID:12447611](https://pubmed.ncbi.nlm.nih.gov/12447611/)
- Tiwawech D, Srivatanakul P, Karalak A, Ishida T (2008). Association between EBNA2 and LMP1 subtypes of Epstein-Barr virus and nasopharyngeal carcinoma in Thais. *J Clin Virol*, 42:1–6.[doi:10.1016/j.jcv.2007.11.011](https://doi.org/10.1016/j.jcv.2007.11.011) [PMID:18180201](https://pubmed.ncbi.nlm.nih.gov/18180201/)

- Tsai JH, Tsai CH, Cheng MH *et al.* (2005). Association of viral factors with non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid tumor tissues. *J Med Virol*, 75:276–281. [doi:10.1002/jmv.20267](https://doi.org/10.1002/jmv.20267) [PMID:15602723](https://pubmed.ncbi.nlm.nih.gov/15602723/)
- Wang CP, Chang YL, Ko JY *et al.* (2004). Lymphoepithelial carcinoma versus large cell undifferentiated carcinoma of the major salivary glands. *Cancer*, 101:2020–2027. [doi:10.1002/cncr.20614](https://doi.org/10.1002/cncr.20614) [PMID:15389474](https://pubmed.ncbi.nlm.nih.gov/15389474/)
- Yasui Y, Potter JD, Stanford JL *et al.* (2001). Breast cancer risk and “delayed” primary Epstein-Barr virus infection. *Cancer Epidemiol Biomarkers Prev*, 10:9–16. [PMID:11205495](https://pubmed.ncbi.nlm.nih.gov/11205495/)